Inactive Instrument

Medifocus, Inc.

Equities

MDFZF

CA58470Q1019

Medifocus Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019

March 02, 2020 at 04:59 pm EST

Medifocus Inc. announced earnings results for the third quarter ended December 31, 2019. For the third quarter, the company announced total revenue was USD 530,181 compared to USD 714,510 a year ago. Operating loss was USD 184,881 compared to USD 112,835 a year ago. Net loss was USD 451,398 compared to USD 279,938 a year ago. For the nine months, total revenue was USD 1.621 million compared to USD 2.156 million a year ago. Operating loss was USD 616,901 compared to USD 298,575 a year ago. Net loss was USD 1.408 million compared to USD 949,919 a year ago.

Latest news about Medifocus, Inc.

Medifocus Inc. Announces Resignation of Mirsad Jakubovic as Chief Financial Officer	20-08-21	CI
Medifocus Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019	20-03-02	CI
Medifocus Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2019	19-11-29	CI
Medifocus Inc. Reports Earnings Results for the First Quarter Ended June 30, 2019	19-08-29	CI
Medifocus Inc. Reports Earnings Results for the Full Year Ended March 31, 2019	19-07-30	CI
Medifocus Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	19-02-28	CI
Medifocus, Inc. Announces Global Market Expansion with Prolieve Performed and Reimbursed by Insurance Carriers in Hong Kong	19-01-03	CI
Medifocus, Inc. Announces FDA PMA Supplement Approval for New Labeling	18-12-03	CI
Medifocus Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2018	18-11-13	CI
Medifocus Inc. Reports Unaudited Consolidated Earnings Results for the Quarter Ended June 30, 2018	18-09-13	CI
Medifocus, Inc. Announces Successful Completion of FDA Post Approval Study for the Prolieve (R) Thermodilatation(Tm) System	18-06-05	CI
Medifocus Inc. Enters into an Exclusive Distribution Agreement with Amos Gazit, Ltd to Market and Distribute Proven Prolieve® Thermodilatation System	18-01-09	CI
Medifocus, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2017	17-08-28	CI
Medifocus, Inc. Auditor Raises 'Going Concern' Doubt	17-07-30	CI
Medifocus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016	17-03-16	CI
Medifocus Inc. Reports Operating Results for the Six Months Ended September 30, 2016	16-12-19	CI
Medifocus Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended September 30, 2016	16-12-07	CI
Medifocus Inc. Appoints William Jow as Chief Executive Officer to Replace Augustine Y. Cheung	16-10-03	CI
Medifocus Inc. Announces Board Changes	16-09-14	CI
Medifocus Inc. Announces Earnings Results for the First Quarter Ended June 30, 2016	16-09-14	CI
Medifocus Inc. Auditor Raises 'Going Concern' Doubt	16-06-09	CI
Medifocus Inc.(TSXV:MFS) dropped from S&P/TSX Venture Composite Index	16-01-18	CI
Medifocus Inc. Signs Research &Development and Manufacturing Agreement with Yuanxing Bio-Pharm Science &Technology Co. Ltd	16-01-13	CI
Medifocus Inc. announced that it has received $0.79 million in funding	15-12-13	CI
Medifocus Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2015	15-12-07	CI

Chart Medifocus, Inc.

Duration

Period

More charts

Company Profile

Medifocus, Inc. is a Canada-based biotechnology company holding a portfolio of medical products encompassing thermotherapy systems. The Company develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostate Hyperplasia (BPH). It owns two focused heat technology platforms: The Endo-thermotherapy Platform and The Adaptive Phased Array (APA) Microwave Focusing Platform. The Endo-thermotherapy Platform from which Prolieve Thermodilatation System (Prolieve) was developed, can potentially be used to treat cancers in prostate, rectal, cervical and esophageal. The APA Microwave Focusing Platform directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company's APA 1000 Breast Cancer Treatment System was developed from the APA technology platform.

Sector

More about the company